UroGen Pharma
Founded Year
2005Stage
IPO | IPOTotal Raised
$7MDate of IPO
5/4/2017Market Cap
0.23BStock Price
9.90Revenue
$0000About UroGen Pharma
UroGen Pharma (NASDAQ: URGN), fka Theracoat, is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC. In addition, UroGen is developing two additional clinical-stage drug candidates, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer and BotuGel, for the treatment of overactive bladder and interstitial cystitis.
Missing: UroGen Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: UroGen Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing UroGen Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
UroGen Pharma is included in 3 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Medical Devices
3,088 items
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
UroGen Pharma Patents
UroGen Pharma has filed 18 patents.
The 3 most popular patent topics include:
- Dosage forms
- Drug delivery devices
- Immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/24/2022 | 2/14/2023 | Dosage forms, Drug delivery devices, Kidney diseases, Rare diseases, Routes of administration | Grant |
Application Date | 3/24/2022 |
|---|---|
Grant Date | 2/14/2023 |
Title | |
Related Topics | Dosage forms, Drug delivery devices, Kidney diseases, Rare diseases, Routes of administration |
Status | Grant |
Latest UroGen Pharma News
May 11, 2023
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent developments. “2023 is off to a promising start as we reported double-digit year-over-year growth in worldwide JELMYTO net sales during the first quarter,” said Liz Barrett, President, and
UroGen Pharma Frequently Asked Questions (FAQ)
When was UroGen Pharma founded?
UroGen Pharma was founded in 2005.
Where is UroGen Pharma's headquarters?
UroGen Pharma's headquarters is located at 9 Ha’Ta’asiya St, Ra'anana.
What is UroGen Pharma's latest funding round?
UroGen Pharma's latest funding round is IPO.
How much did UroGen Pharma raise?
UroGen Pharma raised a total of $7M.
Who are the investors of UroGen Pharma?
Investors of UroGen Pharma include Pontifax and CHealth Fund.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.